12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TC-6987: Completed Phase II enrollment

Targacept disclosed in its 4Q11 earnings that it completed enrollment of about 90 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating once-daily...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >